The global epigenetics market size is expected to reach USD 39.15 billion by 2030, registering a CAGR of 15.10% from 2023 to 2030, according to a new report by Grand View Research, Inc. The market is being driven by factors, such as the rise in funding, investment & regulatory approvals for epigenetics research & development, the expansion of the use of epigenetic enzymes in drug discovery & development, and the decreasing cost of genome sequencing. Since epigenetics has demonstrated beneficial applications outside of cancer, commercial expansion is envisaged.The rising demand for understanding epigenetic alterations at the molecular level, as well as the advancement of medicinal treatments, would likely push these organizations to support research and development programs.
Furthermore, initiatives, such as the Epidemiology and Genomics Research Program (EGRP), provide incentives for research efforts aimed at better-comprehending cancer genesis and consequences.A few organizations that help fuel the market's rise are the International Human Epigenome Consortium (IHEC), the National Cancer Institute (NCI), and the National Institutes of Health (NIH). These organizations support funding and help for initiatives involving product development and R&D in the field of epigenetics. For instance, the National Institutes of Health aggressively promotes cutting-edge epigenetic research worldwide through its common fund epigenomics program.
Request a free sample copy or view report summary: Epigenetics Market Report
By product, the reagents segment accounted for the largest revenue share of 31.50% in 2022 owing to the existence of a number of technology platforms that facilitate analysis at gene, protein, or cellular levels, which encourages innovation in the global marketplace
By application, the oncology segment accounted for the largest revenue share of 69.23% in 2022. The segment is expanding as a result of the increased incidence of cancer and the number of cancer-related fatalities globally
By technology, the histone acetylation segment is anticipated to register the fastest CAGR of 15.8% from 2023 to 2030 due to its improved efficacy as a result of the development of innovative methods
North America dominated the market with the highest revenue share of 38.18% in 2022 owing to government support and increasing R&D funding by government and private organizations
Grand View Research has segmented the global epigenetics market report on the basis of product, application, technology, and region:
Epigenetics Product Outlook (Revenue, USD Million, 2018 - 2030)
Reagents
Kits
Chip sequencing kit
Whole Genomic Amplification Kit
Bisulfite Conversion kit
RNA sequencing kit
Others
Instruments
Enzymes
Services
Epigenetics Technology Outlook (Revenue, USD Million, 2018 - 2030)
DNA Methylation
Histone Methylation
Histone Acetylation
Large noncoding RNA
MicroRNA Modification
Chromatin structures
Epigenetics Application Outlook (Revenue, USD Million, 2018 - 2030)
Oncology
Solid Tumors
Liquid Tumors
Non-Oncology
Inflammatory Diseases
Metabolic Diseases
Infectious Diseases
Cardiovascular Diseases
Epigenetics Regional Outlook(Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
Australia
South Korea
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
List of Key Players of Epigenetics Market
Roche Diagnostics
Thermo Fisher Scientific, Inc.
Eisai Co. Ltd.
Novartis AG
Element Biosciences, Inc.
Dovetail Genomics LLC.
Illumina, Inc.
ValiRx Plc.
Abcam plc.
"The quality of research they have done for us has been excellent..."